Leerink Partnrs dropped their Q2 2025 EPS estimates for Cencora in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.08 per ...

Cencora has gained 13.5% since the start of the year compared to the 0% move for the Zacks Medical sector and the -6.6% return for the Zacks Medical Services industry. The stock has a great record ...

This is an increase from Cencora ... and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical ...

Walgreens is offloading more shares in drug distributor Cencora as the struggling pharmacy chain looks to generate cash. The latest sale netted about $300 million for Walgreens, and shrinks the ...

Cencora, Inc. is a pharmaceutical sourcing ... over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers.

Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution ...

The result of the 2001 merger between AmeriSource Health and Bergen Brunswig, Cencora (NYSE:COR) supplies pharmaceuticals ... and the ability to control medical costs. Health insurers are also ...

Cencora, which belongs to the Zacks Medical Services industry, posted revenues of $81.49 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.31%. This ...